The largest database of trusted experimental protocols

10 protocols using cd8 buv805

1

Multiparameter Flow Cytometry for Immune Cell Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fluorochrome-conjugated antibodies were used to select and sort cell subsets, analyze T cell phenotypes, and to determine cytokine production. The following antibodies were used in this study, separated by manufacturer (clone is indicated in parentheses). Biolegend: Ki67-PacificBlue (16A8), CD62L-BV510 (MEL-14), CD73-BV605 (TY/11.8), CD44-FITC (IM7), PD1-PEDazzle594 (RMP1–30), TIGIT-PECy7 (1G9), LAG3-BV785 (C9B7W), IFNγ (XMG1.2), TNFα-PECy7 (MP6-XT22), SATB1-AlexaFluor594 (O96C6), TIM3-APC/Fire750 (B8.2C12), OX40-BV711 (OX-86), OX40L-PECy7 (RM134L), Tim3-PerCP/Cy5.5 (B8.2C12), CD8-FITC (53–6.7), CD90.2-PECy7 (30H12), CD90.2-PerCP/Cy5 (53–2.1), CD4-APCCy7 (RM4–5). || BD Biosciences: CD90.2-BUV395 (53–2.1), CD4-BUV496 (GK1.5), CD19-BUV661 (1D3), CD11c-BUV661 (N418), F4/80-BUV661 (T45–2342), NK1.1BUV661 (PK136), TER119-BUV661 (TER-119), CD127-BUV737 (SB/199), CD8-BUV805 (53–6.7), FR4-BV421 (12A5), CTLA4-APCR700 (UC10–4F10–11), NK1.1-eFluor450 (PK136), Ter-119-eFluor450 (Ter119), Rorγt-BV650 (Q31–378), CD62L-BV605 (MEL-14). || Invitrogen: FoxP3-AlexaFluor532 (FJK-16s), CD44-BUV737 (IM7), PD1-SB780 (J43), TOX-eFluor660 (TXRX10), EOMES-PerCP/eFluor710 (Dan11mag), F4/80-eFluor450 (BM8), CD49b-eFluor450 (DX5), CD11c-eFluor450 (N418), PD1-PerCPe710 (J43). || Santa Cruz Biotechnologies: NFATc1-AlexaFluor488 (7A6), CD30L-AlexaFluor680 (RM153).
+ Open protocol
+ Expand
2

Multiparametric Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs were labeled with different combinations of the following antibodies: CD4 BUV737 (BD, clone SK3), CD8 BV786 (BD, clone RPA-T8), CD8 BUV805 (BD, clone SK1), CD3 V500 (BD, clone UCHT1), CD3 eVolve605 (eBioscience clone OKT3), CD27 APC-eFluor780 (eBioscience, clone), CD27 BV510 (Biolegend, clone O323), CD45RA BV650 (BD, clone HI100), CD45RA Qdot655 (Invitrogen, clone MEM-56), CD28 PE-Cy7 (BD, clone 28.2), CX3CR1 APC (eBioscience, clone 2A9-1), CCR7 BV421 (Biolegend, clone G043H7), CD127 BV421 (Biolegend, clone A019D5). Near-IR fixable dye (Invitrogen) was used to exclude dead cells from the analysis. For intracellular staining, the following antibodies were used: Hobit IgM (BD, clone Sanquin-Hobit/1), Eomes eFluor660 (eBioscience, clone WD1928), Tbet BV421 (Biolegend, clone 4B10), Granzyme B AF700 (BD, clone GB11), Perforin FITC (eBioscience, clone dG9), Perforin PE (eBioscience, clone B-D48), Granzyme K PE (Immunotools, clone 24C3), Granzyme K FITC (Immunotools, clone 24C3). To stain for Hobit IgM, a secondary anti-IgM labeled with PE or FITC was used. The cells were labeled according to manufacturer’s instructions. For the intracellular staining, the cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining kit (eBioscience). The samples were measured in PBS 0.5% FCS with a LSR Fortessa (BD). The analysis was done using FlowJo Version 10 software.
+ Open protocol
+ Expand
3

Evaluating SSX2-p103 APL Immunogenicity

Check if the same lab product or an alternative is used in the 5 most similar protocols
6 week-old HHDII-DR1 mice were immunized subcutaneously with 100 µg of an individual SSX2-p103 APL in complete Freund’s adjuvant (Sigma, F5881). Mice were euthanized seven days later and spleens were processed and analyzed via flow cytometry as described above. For these studies, the following antibodies were used: SSX2-p103 HLA-A2 tetramer-APC (NIH Tetramer Core Facility), CD3-FITC (BD 555274), CD4-BUV395 (BD 563790), CD8-BUV805 (BD 564920), PD1-PECF594 (BD 562523), 41BB-PerCPeF710 (eBioscience 46-1371-82), Live/Dead Ghost dye 780 (Tonbo 13-0865-T100) or corresponding fluorescently labeled IgG controls. Examples of flow gating are shown in Supplementary Figs. S1–S6.
+ Open protocol
+ Expand
4

Adoptive Transfer of OT-1 T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For adoptive transfer of OT-1 T cells into B6 mice, OT-1 splenocytes were harvested as described above. CD8 T cells were isolated using immunomagnetic negative selection (StemCell, Vancouver, Canada; 19853), rinsed and suspended in PBS, and 2 × 106 cells were adoptively transferred into 6–10 wk old, female, B6 mice via intraperitoneal injection. The day following transfer, mice were immunized subcutaneously with an individual SIINFEKL APL (100 µg) in complete Freund’s adjuvant (Sigma, F5881) or vehicle. Mice were euthanized at the times indicated, spleens were collected, processed as described above, and analyzed via flow cytometry using the following antibodies: SIINFEKL H2Kb tetramer-BV421 (NIH Tetramer Core Facility), CD3-FITC (BD 555274), CD4-BUV395 (BD 563790), CD8-BUV805 (BD 564920), LAG3-BV711 (BD 563179), PD1-PECF594 (BD 562523), TIM3-APC (eBioscience 17-5871-82), 41BB-PerCPeF710 (eBioscience 46-1371-82), CTLA4-PE (eBioscience 12-1529-42), CD44-BV786 (BD 563736) and Live/Dead Ghost dye 780 (Tonbo 13-0865-T100) or corresponding fluorescently labeled IgG controls.
Data collected on different days was normalized using rainbow beads (Spherotech, Lake Forest, IL; RFP-30-5A).
+ Open protocol
+ Expand
5

Splenocyte Activation and Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols
Splenocytes were cultured at 2 × 106/mL in RPMI 1640 + l-glutamine, 10% FCS, penicillin/streptomycin (200 U/mL), 1% NaPyr, 1% HEPES, 50 µM β-MeOH, and the designated peptide (2 µg/mL). At the time points indicated, cells were stained with the following antibodies: CD3-FITC (BD 555274), CD4-BUV395 (BD 563790), CD8-BUV805 (BD 564920), LAG3-BV711 (BD 563179), PD1-PECF594 (BD 562523), TIM3-APC (eBioscience 17-5871-82), 41BB-PerCPeF710 (eBioscience 46-1371-82), CTLA4-PE (eBioscience 12-1529-42), Live/Dead Ghost dye 780 (Tonbo 13-0865-T100), or corresponding fluorescently labeled IgG controls. Cells were then fixed for 15 min at 4°C in cytofix (BD Biosciences, San Jose, CA; 554655), and frozen in FCS + 10% DMSO. After all time points were collected, cells from all times were thawed, rinsed and resuspended in PBS + 3% FCS + 1 mM EDTA and analyzed by flow cytometry. All antibodies used were at 1:100 dilutions and stained for 30 min at 4°C in a 1:4 dilution of brilliant stain buffer (BD 563794) in PBS + 3% FCS + 1 mM EDTA.
+ Open protocol
+ Expand
6

Antigen-Specific CD8+ T Cell Isolation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cryopreserved health donor PBMC were thawed briefly in a 37 °C water bath. CD8+ T cells were enriched using magnetic beads (Miltenyi Biotec). Cells were washed by centrifugation and then treated with PBS (Gibco, #14190-250) containing benzonase (Millipore, #70664) and 50 nM Dasatinib (Axon Medchem, #1392) for 45 min at 37 °C. Cells were transferred to a 96-well assay block (Corning, #3960), centrifuged, and supernatant was aspirated. The appropriate custom Immudex dCODE-PE dextramer pool (Copenhagen, Denmark) was added at 1 µl/100 µl reaction for 30 min in dark at room temperature. Next, the fluorochrome-labeled surface markers were added, and the cells were incubated for additional 30 min at 4 °C. After washes, the cells were immediately sorted. Flow cytometry antibody staining, and washes were performed in staining buffer (BD, #554657). Surface markers for FACS included the following markers and fluorophores: Live/Dead—DAPI (Sigma, #10236276001), CD3 BUV737 (BD Biosciences, #612750), CD4 BV510 (BD Biosciences, #563919), CD8 BUV805 (BD Biosciences, #612889), CCR7 AF647 (BioLegend #353218), and CD45RO BV605 (BioLegend #304238).
+ Open protocol
+ Expand
7

CD8+ T Cell Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
B cells or dendritic cells (DCs) were enriched from splenocytes of OT-1 or B6 mice inoculated with Flt3 ligand-expressing B16 tumor cells25 (link) using PE-labeled antibodies specific for either CD19 or CD11c (StemCell, Seattle, WA, Cat.# 17,684) as previously described.26 (link) Similarly, CD8 + T cells were isolated using a negative selection CD8 + T-cell isolation kit (StemCell, Cat. # 19,853). After enrichment, each APC subset, and a subset of purified T cells, were cultured as described above with 2 µg/mL SIINFELK or the HLA-A2 sequence from SSX2 (RLQGISPKI) as a nonspecific control peptide. Naïve OT-1 T cells were added to each cell type at a 1:1 ratio and incubated for three days, after which cells were stained and analyzed by flow cytometry with the following panel: CD3-FITC (BD 555,274), CD4-BUV395 (BD 563,790), CD8-BUV805 (BD 564,920), LAG-3-BV711 (BD 563,179), PD1-PECF594 (BD 562,523), TIM3–APC (eBioscience 17-5871-82), CTLA4–PECy7 (Tonbo 60-1522-U100), 41BB–PerCPeF710 (eBioscience 46–1371–82), and Live/Dead Ghost dye 780 (Tonbo, San Diego, CA 13–0865–T100).
+ Open protocol
+ Expand
8

Phenotyping Antigen-Specific CD8 T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Splenocytes were collected from naive OT-1 or immunized HHDII-DR1 mice as described above, cultured with 2 µg/mL (unless otherwise indicated) native SSX2-p103, SIINFEKL APL, a non-specific peptide (negative control), or phorbol 12-myristate 13-acetate (40 ng/mL, PMA, Sigma-Aldrich, St. Louis, MO; P8139) and ionomycin (2.6 µg/mL, Fisher Scientific, Waltham, MA; ICN15507001) as a positive control. After two hours golgistop (0.67µL/mL, BD 554724) was added. Cells were incubated for six additional hours (8 hours total), after which intracellular cytokine staining was performed as per the manufacturer’s protocol (Cytofix/Cytoperm Kit, BD 554714). Antibodies used for cells surface staining were: CD3-FITC (BD 555274), CD4-BUV395 (BD 563790), CD8-BUV805 (BD 564920), LAG3-BV711(BD 563179), PD1-PECF594 (BD 562523), 41BB-PerCPeF710 (eBioscience 46-1371-82). Antibodies used for intracellular staining were: TNFα-PECy7 (BD 557644), IL2-APC (eBioscience 17-7021-82), IFNγ-PE (BD 554412), and Live/Dead Ghost dye 780 (Tonbo 13-0865-T100) or corresponding fluorescently labeled IgG controls. The number of antigen-specific Th1 cells (expressing IL2 and/or TNFα and/or IFNγ) was determined as a percentage of total CD8 T cells via an “OR” Boolean gate (FlowJo software v10.1).
+ Open protocol
+ Expand
9

Multiparametric Staining of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Thawed cells were resuspended in 2% FBS/PBS and plated in a 96-well V-bottom plate. Antibody cocktails were prepared in FACS buffer (0.1% BSA/0.1% sodium azide/PBS). Cells were pelleted by centrifugation at 490 g for 5 min at 4 °C. Cells were then stained with 50 μL of Zombie UV Fixable viability dye (diluted 1/500 in PBS) for 20 min on ice in the dark. Cells were washed 3 times with FACS buffer. Cells were then incubated with 50 μL of blocking agents (normal mouse serum 1/20, Fc block 1/10) for 15 min on ice. Antibody cocktails were prepared in FACS Buffer and 50 μL added to each sample and then incubated for 30 min on ice in the dark. Cells were washed 3 times in FACS buffer and then fixed by resuspending in 150 μL of 1% formaldehyde for 20 min at room temperature. Cells were then washed and resuspended in FACS buffer and run on FACSymphony (BD Pharmingen). Samples were analyzed using FlowJo software (Tree Star).
Intracellular staining for MX-1 was performed for 1 × 105 thawed PBMC using the Transcription Factor Buffer Set (BD Biosciences) according to the manufacturer's directions. Permeabilized cells were stained with CD3-PerCP-Cy5.5, CD4-BUV395, CD8-BUV805, CD45RA-BUV737, CD27-APC-R700 (BD Biosciences) and 1 μg MX-1-AF647 (Abcam) according to manufacturer's directions and analyzed on a 5-laser Fortessa X20 (BD Biosciences) as previously described [30 (link)].
+ Open protocol
+ Expand
10

Multiparameter Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies were used (from BioLegend): CD4-APC-Cy7 (clone OKT4), CD8-PerCp-Cy5.5 (clone SK1), TIM-3-BV510 (clone F38-2E2), CD39-FITC or APC-Cy7 (clone A1), CD95-PE (clone DX2), CD3-PacBlue (clone HIT3a), PD-1-BV421 (clone EH12.2H7), and CD3-PE (clone HIT3a); (from eBioscience): PD-1-PE-Cy7 (clone eBio J105), LAG-3-PE (clone 3DS223H), CD45RO-PE-Cy7 (clone UCHL1), and CD45-PerCp-Cy5.5 (clone HI30); (from BD): CD45RA-FITC or BV711 (clone HI100), CCR7-BV421 (clone 150503), CD122-BV510 (clone Mik-β3), CD62L-BV605 (clone DREG-56), CD4-BUV395 (clone SK3), and CD8-BUV805 (clone SK1).
The anti–CD19-28z CAR antibody was provided by B. Jena and L. Cooper, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX. The anti–HA-28z CAR antibody was provided by the National Cancer Institute, Frederick, MD. Each was conjugated with Dylight288 and/or 650 antibody labeling kits (Thermo Fisher).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!